SEC Form 4	
------------	--

П

I

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average b	urden
hours par response:	0 5

L		
	hours per response:	0.5
	Estimateu average buruen	

	s of Reporting Person r Δ	n*	2. Issuer Name and Ticker or Trading Symbol Aerpio Pharmaceuticals, Inc. [ARPO]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Saller Mullee				X	Director	Х	10% Owner			
Satter Muneer A (Last) (First) (Middle) C/O AERPIO PHARMACEUTICALS, INC. 9987 CARVER ROAD, SUITE 420 (Street) CINCINNATI OH 45242		ALS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 12/28/2018		Other (specify below)					
9987 CARVER ROAD, SUITE 420			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group Filing (Check Applicable					
(Street)				X	Form filed by One I	Report	ing Person			
CINCINNATI	OH	45242			Form filed by More Person	than C	One Reporting			
(City)	(State)	(Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table 1- Non-Derivative Securities Acquired, Disposed of, or Denenciary Owned													
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			saction Disposed Of (Beneficially (D) or Indir Owned Following (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
					Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	12/28/2018		P ⁽¹⁾		20,000	A	\$1.7186(2)	5,458,017	Ι	See footnote ⁽³⁾			
Common Stock	12/31/2018		P ⁽¹⁾		20,000	A	\$1.745 ⁽⁴⁾	5,478,017	Ι	See footnote ⁽³⁾			
Common Stock	01/02/2019		P ⁽¹⁾		20,000	A	\$1.9419 ⁽⁵⁾	5,498,017	Ι	See footnote ⁽³⁾			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(0.9., P	uto, 0	uno,	wan	unto,	option3, (Janacoj				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Nu of Deriv Secu Acqu (A) of Dispo of (D) (Instr and 5	ative rities ired osed	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		ount of Derivative surities Security derlying (Instr. 5) rivative surity (Instr. 3		Ownership Form:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. All shares were purchased by Satter Medical Technology Partners, L.P.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.655 to \$1.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.71 to \$1.76. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.845 to \$2.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were purchased in m

<u>/s/ Robert M. Hayward, by</u>

01/02/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Power of Attorney